**Pancreatic Islet Function Tests**

**Marisa E. Desimone, M.D.,** Assistant Professor of Medicine, SUNY Upstate Medical University, Syracuse NY, desimoma@upstate.edu

**Ruth S. Weinstock, M.D., PhD,** SUNY Distinguished Service Professor, SUNY Upstate Medical University, Syracuse NY, weinstor@upstate.edu

**Updated: April 10, 2018**

**ABSTRACT**

**Objective:** To describe testing indications and protocols for the evaluation of pancreatic islet function. **Methods:** A review of the literature and consensus guidelines concerning testing of pancreatic islet function was performed. **Results:** Indications for screening for diabetes mellitus are reviewed. Diagnostic criteria for diagnosis are fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l) or random ≥200 mg/dl (11.1 mmol/l)] with hyperglycemic symptoms, hemoglobin A1c (HbA1c) ≥6.5%, and oral glucose tolerance testing (OGTT) 2-h ≥200 mg/dl (11.1 mmol/l) after 75 g glucose. One-step and two-step strategies for diagnosing gestational diabetes using pregnancy-specific criteria as well as use of the 2-h 75-g OGTT for the postpartum testing of women with gestational diabetes (4-12 weeks after delivery) are described. Testing for other forms of diabetes with unique features are reviewed, including the recommendation to use the 2-h 75 g OGTT to screen for cystic fibrosis-related diabetes, and genetic testing for monogenic diabetes syndromes including neonatal diabetes and maturity-onset diabetes of the young (MODY). Elevated measurements of pancreatic autoantibodies [e.g. to the 65-KDa isoform of glutamic acid decarboxlase (GAD65), tyrosine phosphatase related islet antigen 2 (IA-2), insulin (IAA), and zinc transporter (ZnT8)] suggest autoimmune type 1 diabetes (vs type 2 diabetes). The use of autoantibody testing in diabetes screening programs are recommended only in first degree relatives of an individual with type 1 diabetes or in research protocols. Use of c-peptide testing and OGTTs to examine insulin secretory reserve and intravenous glucose tolerance testing are also reviewed. These tests are primarily used in research studies. Evaluation of glycemic control is discussed, with special attention to HbA1c and its correlation with mean blood glucose levels as well as assays of other glycated serum proteins. Finally, protocols used to evaluate hypoglycemia [glucose < 55 mg/dl (3.1 mmol/l)] are described, such as the supervised prolonged fast, during which measurements of glucose, insulin, c-peptide, oral insulin secretagogues, proinsulin, and beta-hydroxybutyrate are obtained. Insulinoma is suggested by elevated insulin, proinsulin and c-peptide levels, beta-hydroxybutyrate < 2.7 mmol/l and undetectable insulin secretagogues. Use of the mixed meal test, glucagon tolerance test, c-peptide suppression test and evaluation of autoimmune hypoglycemia are also reviewed. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

**SCREENING FOR DIABETES MELLITUS**

Early detection and treatment of diabetes mellitus is important in preventing the chronic and acute complications of this disease. Individuals with symptoms suggestive of hyperglycemia, such as polyuria, polyphagia, polydipsia, unexplained weight loss, blurred vision, excessive fatigue, or infections or wounds that heal poorly should be promptly tested.

The American Diabetes Association (ADA) recommends routinely screening for type 2 diabetes in adults every three years beginning at age 45. In asymptomatic people, testing for type 2 diabetes should be considered in adults of any age if they are overweight or obese (BMI ≥ 25 kg/m2, or ≥ 23 kg/m2 if Asian) if they have additional risk factors as listed below in Table 1. Repeat screening should be performed at least every three years. Patients with prediabetes should be screened yearly (1). The US Preventive Services Task Force recommends glucose screening for all asymptomatic overweight or obese adults ages 40-70 (2); the American Association of Clinical Endocrinologists recommends screening at risk individuals at any age (3).

**Table1. Risk Factors for the Development of Type 2 Diabetes (1)**

|  |
| --- |
| Physical inactivity |
| First-degree relative with diabetes |
| High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander) |
| Women who delivered a baby weighing >9 lb or were diagnosed with Gestation Diabetes |
| Hypertension (≥140/90 mm Hg or on therapy for hypertension) |
| HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L) |
| Women with polycystic ovary syndrome |
| HbA1C ≥5.7%, Impaired Glucose Tolerance (IGT), or Impaired Fasting Glucose (IFG) on previous testing |
| Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans) |
| History of cardiovascular disease |

Type 2 diabetes is becoming a growing problem in children and adolescents in high-risk populations. To address this issue, the ADA recommends screening overweight children (BMI >85th percentile for age and gender, weight for height >85th percentile or weight > 120% of ideal for height) every 3 years, beginning at age 10 or at the onset of puberty, if they have 1 or more additional risk factors listed below in Table 2. Repeat testing should be done more frequently if BMI is increasing (1).

**Table 2. Risk Factors for Type 2 Diabetes in Children and Adolescents**

|  |
| --- |
|  Family history of type 2 diabetes (first and second-degree relatives) |
| High risk ethnicity (Native Americans, African-Americans, Latino, Asian/Pacific Islanders) |
| Signs of insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, small-for-gestational-age birth weight, or polycystic ovary syndrome) |
| Maternal history of diabetes or gestational diabetes during child's gestation |

**DIAGNOSING DIABETES**

The diagnosis of diabetes can be made using the fasting plasma glucose, random plasma glucose, oral glucose tolerance test or hemoglobin A1c (HbA1c) (4). Testing should be performed on 2 separate days using one or more of the above tests, unless unequivocal hyperglycemia is present. The use of the HbA1c assay was recommended for the diagnosis of diabetes in 2009 by an International Expert Committee (5). HbA1c levels reflect overall glycemic control and correlate with the development of microvascular complications. An HbA1c > 6.5% on two separate occasions can be used to diagnose diabetes. An HbA1c level of 6.0% to less than 6.5% identifies high risk of developing diabetes. The ADA considers a HbA1c of 5.7% to 6.4% high risk for developing diabetes (1). HbA1c should not be used to diagnose gestational diabetes.

**Table 3. ADA Criteria for the Diagnosis of Diabetes (1)**

|  |
| --- |
| HbA1C ≥6.5%. The test should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay. |
| FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h. |
| 2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) during an Oral Glucose Tolerance Test (OGTT). The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. |
| In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L) without repeat testing for confirmation.  |

**Fasting and Random Plasma Glucose**

Fasting plasma glucose is one method recommended by the ADA for the diagnosis of diabetes in children and non-pregnant adults (1). If fasting plasma glucose is abnormal in an asymptomatic individual it should be repeated on at least one additional day to confirm the diagnosis of diabetes unless unequivocal hyperglycemia is present (1,4). The test should be performed after an 8 hour fast. For routine clinical practice, fasting plasma glucose may be preferred over the oral glucose tolerance test because it is rapid, easier to administer, is more convenient for patients and providers, and has a lower cost (1). The use of the oral glucose tolerance test, however, may be warranted in high risk individuals with normal fasting plasma glucose levels.

**Table 4. Fasting Plasma Glucose Criteria**

|  |  |
| --- | --- |
|  | **Fasting Plasma Glucose** |
| Normal glucose tolerance | <100 mg/dl (5.6 mmol/l) |
| Impaired fasting glucose (pre-diabetes) | 100-125 mg/dl (5.6-6.9 mmol/l) |
| Diabetes mellitus | ≥126 mg/dl (7.0 mmol/l) |

A random plasma glucose level, which is obtained at any time of the day regardless of the time of the last meal, can be used in the diagnosis of diabetes. A random plasma glucose level of >200 mg/dl (11.1 mmol/l) in a patient with classic symptoms of hyperglycemia is diagnostic of diabetes and a confirmatory test is not needed. In the absence of symptoms of hyperglycemia, the diagnosis should be confirmed by repeating the random plasma glucose or by obtaining a fasting plasma glucose level, oral glucose tolerance test or HbA1c on at least one additional occasion.

For the diagnosis of diabetes, standard venous plasma glucose specimens should be obtained. Specimens should be processed promptly, since glucose is metabolized at room temperature and the process is influenced by storage temperature and storage time. This breakdown is accelerated in the presence of bacteria or leukocytosis. If serum is in contact with cells for a prolonged length of time (>30 min), the addition of a preservative such as sodium fluoride is recommended.

Whole blood glucose specimens obtained with point-of-care devices should not be used for the diagnosis of diabetes because of the inaccuracies associated with these methods. Capillary and venous whole blood glucose concentrations are approximately 15% lower than plasma glucose levels in fasting specimens.

**Oral Glucose Tolerance Test (OGTT)**

OGTTS FOR THE DIAGNOSIS OF DIABETES IN NON-PREGNANT INDIVIDUALS

Formal oral glucose tolerance tests can be used to establish the diagnosis of diabetes mellitus. They are more cumbersome and costly than the fasting plasma glucose test, however, the use of only the fasting plasma glucose may not identify a proportion of individuals with impaired glucose tolerance or diabetes (6). A plasma glucose level 2-hours after a glucose challenge may identify additional individuals with abnormal glucose tolerance who are at risk for microvascular and macrovascular complications, particularly in high risk populations in which postprandial (versus fasting) hyperglycemia is evident early in the disease (7,8).

When using an OGTT, the criteria for the diagnosis of diabetes is a 2 h glucose >200 mg/dl (11.1 mmol/l) after a 75 gram oral glucose load (ADA and WHO criteria). The 75 gram glucose load should be administered when the patient has ingested at least 150 grams of carbohydrate for the 3 days preceding the test and after an overnight fast. Dilution of the 75 gram oral glucose load (300-900 ml) may improve acceptability and palatability without compromising reproducibility (9). The patient should not be acutely ill or be taking drugs that affect glucose tolerance at the time of testing, and should abstain from tobacco, coffee, tea, food, alcohol and vigorous exercise during the test.

**Table 5. Oral Glucose Tolerance Test Glucose Criteria**

|  |  |
| --- | --- |
|  | **2-h Plasma Glucose (after 75 gram Glucose Load)** |
| Normal glucose tolerance | <140 mg/dl (7.8 mmol/l) |
| Impaired glucose tolerance(pre-diabetes) | 140-199 mg/dl (7.8-11.1 mmol/l) |
| Diabetes mellitus | ≥200 mg/dl (11.1 mmol/l) |

OGTTS FOR THE DIAGNOSIS OF GESTATIONAL DIABETES

The prevalence of gestational diabetes (GDM) varies among racial and ethnic groups and between screening practices, testing methods and diagnostic criteria. The overall frequency of GDM in the 15 centers participating in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study was 17.8% (10), and regional estimates may vary from 10% to 25 % depending on the population studied (11). The prevalence increases with increased number of risk factors, such that 33% of women with 4 or more risk factors have gestational diabetes (12). This condition is important to diagnose early because of the increased perinatal morbidity associated with poor glycemic control.

The US Preventive Task Force recommends screening for gestational diabetes in asymptomatic women after 24 weeks (13); the ADA recommends screening all pregnant women routinely between 24 and 28 weeks gestation. If the woman is at high risk, however, screening should be performed at the initial prenatal visit (1).

**Table 6. Risk Factors for the Development of Gestational Diabetes**

|  |
| --- |
| Overweight or obese |
| Previous history of Impaired Glucose Tolerance, gestational diabetes or delivery of a baby weighing >9 lb. |
| Glycosuria or history of abnormal glucose tolerance |
| Family history of diabetes (especially first degree relative) |
| Polycystic ovarian syndrome, hypertension, glucocorticoid use |
| History of poor obstetric outcome |
| Age (>25 years) |
| High risk ethnicity |
| Multiple gestation |

**Table 7. Low Risk for the Development of Gestational Diabetes**

|  |
| --- |
| Age (< 25 years) |
| Normal weight pre-pregnancy |
| Low risk ethnicity |
| No first degree relatives with diabetes |
| No history of abnormal glucose tolerance |
| No history of poor obstetric outcome |

**Table 8. Time of Initial Testing for Gestational Diabetes**

|  |  |
| --- | --- |
| **Risk of Development of Gestational Diabetes** | **Time of Initial Testing for Gestational Diabetes** |
| Low risk | 24-28 weeks gestation |
| Average risk | 24-28 weeks gestation |
| High risk | As soon as feasible; repeat at 24-28 weeks if earlier testing normal |

More than one method has been recommended for the screening and diagnosis of gestational diabetes. The criteria for the diagnosis of this condition remain controversial because the glucose thresholds for the development of complications in pregnancies with diabetes remain poorly defined. Currently, the ADA suggests screening for GDM with either the “one-step” or “two-step” approach (1). Long term outcome studies evaluating pregnancies complicated by GDM are currently underway and hopefully a uniform approach will be adopted.

One-Step Strategy:

The International Association of Diabetes and Pregnancy Study Group (IADPSG), an international consensus group with representatives from multiple obstetrical and diabetes organizations including the ADA recommend that all women not previously known to have diabetes undergo a 75-gram 2 hour OGTT at 24-28 weeks of gestation. This approach, which has been adopted internationally, is expected to increase the prevalence of GDM as only one abnormal value is sufficient to make the diagnosis (4,14). In 2017, the American College of Obstetricians and Gynecologists (ACOG) stated that clinicians may make the diagnosis of gestational diabetes based on only one elevated blood glucose value if warranted, based on their population, although this organization still supports the “two step” approach for diagnosis of GDM (15).

**Table 9.** **Oral Glucose Tolerance Test Glucose Criteria for the Diagnosis of GDM**

|  |
| --- |
| **75-gram 2- hour OGTT:** Performed in the morning after an overnight fast of at least 8 hoursGDM is diagnosed when any of the following values are exceeded: |
| Fasting | ≥ 92 mg/dL (5.1 mmol/L) |
| One Hour | ≥ 180 mg/dL (10.0 mmol/L) |
| Two Hour | ≥ 153 mg/dL (8.5 mmol/L) |

These glucose thresholds were based on outcome data of the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study that conveyed an odds ratio for adverse maternal, fetal and neonatal outcomes of at least 1.75 based on fully adjusted logistic regression models (16).

Two-Step Strategy:

The American College of Obstetricians and Gynecologists (ACOG) as well as the National Institutes of Health (NIH) are in support of the "two step" approach which consists of universal screening of all pregnant women with a 50-gram glucose challenge regardless of timing of previous meals, followed by a 100-gram three-hour OGTT in screen positive patients (15, 17).

In the two-step approach, first a 50 gram oral glucose load is administered regardless of the timing of previous meals. The following thresholds have been defined as a positive screen: ≥130 mg/dL, ≥135 mg/dL, or ≥140 mg/dL (7.2 mmol/L, 7.5 mmol/L, or 7.8 mmol/L); the lower threshold has an estimated sensitivity and specificity of 88-99% and 66-77% compared to 70-88% and 69-89% respectively for the higher cutoff (1).

**Table 10. Abnormal Glucose Level on Screening Test**

|  |
| --- |
| **50 gram Glucose Load** |
| 1-h Plasma Glucose | ≥130 mg/dl (7.8 mmol/l) |

If the screening test is abnormal, the diagnosis of gestational diabetes should be confirmed using a formal OGTT. This test should be performed after an overnight (8-14 h) fast. It is generally recommended that the woman ingest at least 150 grams of carbohydrate/day for the 3 days prior to testing to prevent false positive results; however the necessity of this preparatory diet in normally nourished women has been challenged (18). At least 2 of the following 4 venous plasma glucose levels must be attained or exceeded to make the diagnosis of GDM (1).

**Table 11. Oral Glucose Tolerance Test Glucose Criteria For the Diagnosis of GDM**

|  |  |  |
| --- | --- | --- |
|  | **Carpenter/Coustan** | **National Diabetes Data Group** |
| Fasting | ≥95 mg/dl (5.3 mmol/l) | ≥105 mg/dl (5.8 mmol/l) |
| One Hour | ≥180 mg/dl (10.0 mmol/l) | ≥190 mg/dl (10.6 mmol/l) |
| Two Hours | ≥155 mg/dl (8.6 mmol/l) | ≥165 mg/dl (9.2 mmol/l) |
| Three Hours | ≥140 mg/dl (7.8 mmol/l) | ≥145 mg/dl (8.1 mmol/l) |

OGTTS FOR POSTPARTUM TESTING OF WOMEN WITH GESTATIONAL DIABETES

Women with a history of GDM are at a higher risk of developing type 2 diabetes than women without GDM (19, 20). Women at the highest risk are those with multiple risk factors, those who had more severe gestational diabetes and those with poorer beta cell function (12). The ADA recommends testing women 4-12 weeks after delivery using a two- hour 75 gram OGTT. Women with normal results should be retested every 1-3 years. It is recommended that subjects with impaired fasting glucose or impaired glucose tolerance be retested on a yearly basis (1).

OGTTS FOR DIAGNOSIS OF CYSTIC FIBROSIS-RELATED DIABETES

Diabetes is common in patients with cystic fibrosis and is associated with adverse effects on nutritional status as well as pulmonary function. Annual screening for diabetes is recommended for individuals over age 10 with cystic fibrosis. HbA1c and fructosamine can be inaccurate in this population. The use of the 2 hour 75 gm OGTT is recommended for the screening of healthy outpatients. For patients receiving continuous drip feedings, laboratory glucose levels at the midpoint or immediately after feedings should be obtained. The diagnosis of diabetes is based on glucose levels ≥200 mg/dL on 2 separate occasions. If the patient is acutely ill or ingesting glucocorticoids, a FPG ≥126 mg/dL or 2 hour postprandial glucose ≥200 mg/dL that persists for >48 hours is sufficient to diagnose diabetes (21, 22).

OGTTS FOR ESTIMATING INSULIN SENSITIVITY AND SECRETION

The hyperinsulinemic euglycemic insulin clamp procedure is the gold standard for measuring insulin resistance, and the hyperglycemic clamp is the gold standard for measuring insulin secretion in research studies. Fasting data and data from OGTTs are more often used due to ease of performance and lower cost. A simple widely used research method, the Homeostasis Model (HOMA), uses fasting glucose (G) and insulin (I) levels [or c-peptide (C) instead of insulin] to estimate beta cell function and insulin sensitivity. The HOMA calculator as well as additional information concerning this method can be found at: http://www.dtu.ox.ac.uk/homacalculator/. Insulin secretion has also been estimated using the Insulinogenic Index [IGI; ∆I30/∆G30] and the C-peptide Index (∆C30/∆G30). Additional estimates of insulin sensitivity include the Quantitative Insulin Sensitivity Check Index [QUICKI; 1/log(FI) + log (FG)] and the Whole Body Insulin Sensitivity Index [WBISI]. The Oral Disposition Index is a measure of insulin secretion relative to insulin sensitivity [1/IF x (∆C30/∆G30)]. These measures are not used in routine clinical care.

**Intravenous Glucose Tolerance Test**

The short intravenous glucose tolerance test (IVGTT) is used in research studies to assess first phase insulin release. This acute insulin secretory response is typically lost early in the development of both type 1 and type 2 diabetes due to reduction of beta cells and islet cell dysfunction. Abnormal IVGTT results can occur prior to the onset of the diabetes. The test is performed after an overnight 10 h fast, and the patients are instructed to ingest at least 150 grams of carbohydrate for the 3 days preceding the test. A 25 gram glucose bolus (of a 25% glucose solution) is given intravenously, and the acute insulin response calculated from the third to fifth minute after the glucose bolus. The short intravenous glucose tolerance test is sometimes used to assess pancreatic function after pancreatic transplantation.

In the Diabetes Prevention Trial Type 1, a glucose load was given intravenously (0.5 g/kg body weight up to a maximum of 35 grams) over 3 minutes, and insulin levels at 1 and 3 minutes post-load were used to estimate acute insulin production (23). Individuals with low insulin response (<100 uU/ml) and positive autoantibodies were at high risk of developing type 1 diabetes. Until effective interventions are established, however, the routine use of this test for the detection of early type 1 diabetes is not recommended.

The standard intravenous glucose tolerance test is used in research studies to estimate insulin sensitivity (SI) and glucose effectiveness (SG) using minimal model methodology. The procedure for the standard intravenous glucose tolerance test is to intravenously inject glucose (0.33 g/kg body weight) over 2 minutes and to frequently sample for glucose and insulin over 3-4 hours. Modifications include the addition of a tolbutamide (125 mg/m2) or insulin (20-30 mU/kg) infusion 20-25 minutes after the glucose load. These tests are not used in clinical practice.

**C-Peptide Testing**

During the processing of proinsulin to insulin in the beta cell of the pancreas, the 31 amino acid connecting peptide which connects the A and B chains, called c-peptide, is enzymatically removed and secreted into the portal vein. C-peptide circulates independently from insulin and is mainly excreted by the kidneys. Levels are elevated in renal failure. Standardization of different c-peptide assays is still suboptimal. The major use of c-peptide measurements is in the evaluation of hypoglycemia.

C-peptide testing has been used in studies to examine insulin secretory reserve. In type 1 diabetes, there is progressive loss of c-peptide with progressive destruction of the beta cells in the islets of the pancreas. Although c-peptide levels in many individuals with long-standing type 1 diabetes are extremely low or undetectable, there is heterogeneity in residual beta cell function with detectable c-peptide being more common in adult-onset type 1 diabetes (24). In type 1 diabetes, c-peptide concentrations ≥0.2 nmol/L are associated with better glycemic control. In type 2 diabetes, there is also a progressive loss of beta cell function over many years, with progressive loss of insulin secretory capacity and decreasing c-peptide levels. Fasting and glucose-stimulated c-peptide levels have been used to distinguish type 1 (severe insulin deficiency) from type 2 diabetes with limited success and poor discrimination.

C-peptide stimulation using glucagon or a mixed meal such as Sustacal, has also been used to help differentiate between type 1 and type 2 diabetes, and to determine the need for insulin therapy in type 2 diabetes. In the glucagon stimulation test, glucose, insulin and c-peptide levels are measured 6 and 10 min after the intravenous injection of 1 mg of glucagon. Normal stimulation of c-peptide is a 150-300% elevation over basal levels. In the mixed meal tolerance test, Sustacal (6 mg/kg up to a maximum or 360 ml) is ingested over 5 minutes, and glucose and c-peptide are measured 90 min after oral ingestion.

These tests have had limited general clinical utility since they do not reliably discriminate between patients who require insulin therapy. They have been used in research studies and in the evaluation of patients after pancreatectomy and pancreatic transplantation. In the Diabetes Control and Complications Trial, a basal c-peptide value of <0.2 pmol/ml and stimulated level of <0.5 pmol/ml were used to confirm the presence of type 1 diabetes at entry (25).

**Pancreatic Autoantibodies**

Islet autoantibodies can be detected early in the development of type 1 diabetes and are considered markers of autoimmune beta cell destruction. They predict progressive beta cell destruction and ultimately beta cell failure. The autoantibodies for which specific immunoassays are available include the 65-KDa isoform of glutamic acid decarboxylase (GAD65), insulin autoantibodies (IAA), zinc transporter antibodies (ZnT8), islet cell antigen 512 autoantibodies (ICA512), and autoantibodies to the tyrosine phosphatase related antigens islet antigen 2 (IA-2) and IA-2b. ICA512 are autoantibodies to parts of the IA-2 antigen. The presence of high levels of 2 or more antibodies is strongly predictive of type 1 diabetes mellitus. These antibodies may be detected before the onset of type 1 diabetes and at the time of diagnosis, and have been used in screening for type 1 diabetes in first-degree relatives of an individual with type 1 diabetes or in research studies related to the early detection, treatment and prevention of type 1 diabetes (www.diabetestrialnet.org). These measurements are not recommended for use in general screening programs in low risk individuals.

Commercially available assays for autoantibodies are sometimes useful in distinguishing early type 1 diabetes from type 2 diabetes. The absence of detection of these antibodies, however, does not exclude the diagnosis of type 1 diabetes. Since insulin antibodies can form in response to insulin therapy, detection can be the result of insulin injections or autoimmune insulin antibody formation. GAD65 antibodies are frequently observed early in the course of type 1 diabetes. They are also present in the rare neurological disorder, stiff-man syndrome, and in some patients with polyendocrine autoimmune disease. The GAD65 and IA-2 assays are considered more sensitive than the IAA assay for the detection of early type 1 diabetes in adults, whereas IAA are more common in young children who develop type 1 diabetes. Although it has been suggested that GAD65 and IA-2 positivity show high diagnostic specificity for type 1 diabetes and may be helpful in determining which type 2 diabetes patients require insulin therapy (or really have type 1 diabetes), the cost-effectiveness of this approach has not been established.

**Genetic Testing for Monogenic Diabetes Syndromes**

Monogenic diabetes syndromes account for 1%-5% of all individuals with diabetes and are primarily classified as neonatal diabetes or Maturity-Onset Diabetes of the Young (MODY). More than 30 affected genes have been described.

**Table 12. When to Consider Genetic Testing for Monogenic Diabetes Syndromes**

|  |
| --- |
| Diabetes diagnosed younger than 6 months of age |
| Diabetes not characteristic of type 1 or type 2 (negative pancreatic auto-antibodies, non-obese, no features of metabolic syndrome) and with a strong family history (diabetes in successive generations suggesting dominant inheritance) |
| Fasting glucose 100-150 mg/dL, stable A1c (5.6-7.6%), especially if non-obese |

NEONATAL DIABETES

The ADA recommends immediate genetic testing for all infants diagnosed with diabetes within the first 6 months of life (1). Common causes of neonatal diabetes include mutations in the following genes: KCNJ11 (potassium inward-rectifying channel, subfamily J, member 11), ABCC8 (ATP-binding cassette, sub-family C, member 8 of the potassium channel), INS (preproinsulin), 6q24 (PLAGL1, HYMA1), GATA6, EIF2AK3 and FOXP3 (see <http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/neonatal-diabetes/> for more details).

MATURITY-ONSET DIABETES OF THE YOUNG (MODY)

MODY most commonly manifests before age 25 years but can be diagnosed in older individuals. The inheritance is typically autosomal dominant. The number of genetic mutations responsible has been increasing each year. Most common forms include: [HNF4A-MODY (hepatocyte nuclear factor-4 alpha; MODY 1)](http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/hnf4a-mody-mody-1/), GCK-MODY (glucokinase; MODY 2), HNF1A-MODY (hepatocyte nuclear factor 1 homeobox A; MODY 3 ), PDX1-MODY (MODY 4), HNF1B-MODY [(hepatocyte nuclear factor-1 beta; MODY 5)](http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/hnf1b-mody-mody-5/),  [NEUROD1-MODY (MODY 6)](http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/other-rare-gene-mutations/), and INS-MODY ([MODY 10)](http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/other-rare-gene-mutations/). Proper diagnosis is critical since treatment approaches will differ depending upon the gene affected. See http://monogenicdiabetes.uchicago.edu/for-healthcare-professionals/mody/ for more information.

**EVALUATION OF GLYCEMIC CONTROL IN DIABETES MELLITUS**

**Hemoglobin A1c**

Glycosylated hemoglobin, or the hemoglobin A1c (HbA1c) assay, is the most widely accepted laboratory test for the measurement of glycemic control and is recommended for routine use in the management of patients with diabetes mellitus. HbA1c levels reflect average blood glucose levels over the preceding 2-3 months. Although the life span of erythrocytes is approximately 120 days, HbA1c levels represent a weighted average of blood glucose levels, with youngest red blood cells, reflecting mean glucose levels over the past month, contributing to a greater extent than older ones.

The International Federation of Clinical Chemistry Working Group on HbA1c defines the HbA1c as the hemoglobin A that is irreversibly non-enzymatically glycosylated at one or both N-terminal valines of the beta-chains of the hemoglobin. Multiple methods have been certified to measure HbA1c. The National Glycohemoglobin Standardization Program, which was started in 1996, has been largely successful in its goal to standardize HbA1c assays throughout the United States to the HPLC method used in the Diabetes Control and Complications Trial. The process has involved certification and proficiency testing, and long-term monitoring of quality control data. Providers should only use laboratories that are certified by the National Glycohemoglobin Standardization Program. Information concerning certified methods and laboratories can be found on their website <http://www.ngsp.org/>.

A consensus statement on the international standardization of HbA1c assays was issued by the American Diabetes Association, the European Association for the Study of Diabetes, the International Diabetes Federation, the International Federation of Clinical Chemistry and Laboratory Medicine, the International Society for Pediatric and Adolescent Diabetes, the Japanese Diabetes Society and the National Glycohemoglobin Standardization Program (26). A1c assays should be calibrated to this reference method and results reported in a standardized manner [A1c (%); A1c (mmol/mol), and estimated average glucose].

The ADA recommends determining HbA1c levels every 3 to 6 months to monitor glycemic control (1). Reducing the HbA1c level to as close to normal as possible is directly related to the reduction of the chronic complications of diabetes in several studies (25, 27-29). The ADA goal HbA1c is <7% (if this can be accomplished safely) but states that lower goals may be appropriate in individual patients. Higher A1c goals may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced complications, and/or comorbid conditions and those in whom a lower goal is difficult to attain (1). The American Association of Clinical Endocrinologists target HbA1c is 6.5% for otherwise healthy patients at low risk for hypoglycemia. HgbA1c targets should be individualized in patients with concurrent illness or those at risk for hypoglycemia (30).

The international A1C-Derived Average Glucose Study (ADAG) utilized frequent self monitoring of blood glucose and continuous glucose monitoring in adults with type 1 diabetes, type 2 diabetes, and no diabetes. The study described a linear relationship between HbA1C and average glucose level (31).

In the ADAG study, there was no significant difference in the regression lines between HbA1C and mean glucose levels among ethnic and racial groups, although there was a trend toward a difference in regression lines between African/African-American and Caucasian adults (30). Other studies have shown differences in HgbA1c by race and ethnicity, although the reasons for this remain unknown and the individual differences within racial groups are greater than the variation between races (32-33). At this time the recommended HgbA1c target does not differ based on ethnicity.

**Table 13. Correlation of HbA1c levels with mean blood glucose levels (31, 34-35)**

|  |  |
| --- | --- |
| **Hemoglobin A1c (%)** | **Approximate Mean Plasma Glucose (mg/dL)** |
|  | **Nathan et al 2008 (ADAG study; reference 31)** | **Beck et al 2017** **(reference 35 )** |
| 6 | 100-152 | 101-163 |
| 7 | 123-185 | 128-190 |
| 8 | 147-217 | 155-218 |
| 9 | 170-249 | 182-249 |
| 10 | 193-282 | 209-273 |

|  |  |
| --- | --- |
| **Hemoglobin A1c (%)** | **Mean Glucose Levels (95% CI; reference 1)** |
| **Fasting (mg/dL)** | **Premeal (mg/dL)** | **Postmeal (mg/dL)** | **Bedtime (mg/dL)** |
| 5.5-6.49 | 122(117-127) | 118(115-121) | 144 (139-148) | 136 (131-141) |
| 6.5-6.99 | 142(135-150) | 139 (134-144) | 164(159-169) | 153(145-161) |
| 7.0-7.49 | 152(143-162) | 152(147-157) | 176 (170-183) | 177(166-188) |
| 7.5-7.99 | 167(157-177) | 155(148-161) | 189(180-197) | 175(163-188) |
| 8.0-8.5 | 178(164-192) | 179(167-191) | 206(195-217) | 222(197-248) |

Depending upon the assay method being used, certain hemoglobinopathies may interfere with results. This problem is highly method-dependent. Inaccurate results may be obtained in the presence of salicylates, chronic alcohol or opiate use, hyperbilirubinemia, liver or renal disease, iron deficiency, vitamin C, vitamin E, hypertriglyceridemia and lead poisoning, recent blood transfusions and when there are conditions of abnormal red blood cell turnover such as in anemia, hemolysis, pregnancy or use of erythropoiesis-stimulating agents. See [www.ngsp.org/interf/asp](http://www.ngsp.org/interf/asp) for a full list of interferences for different methods.

Because of the improved standardization and reference method for the HbA1c assay, both the ADA and an International Expert Committee suggests that a HbA1c > 6.5% on two occasions is diagnostic of diabetes (1,4-5). Benefits of the use of HbA1c for the diagnosis of diabetes are that the test is easy to perform, does not have to be performed in the fasting state, and does not require any special preparation. Potential problems include variations by factors such as ethnicity, possible interference by states such as those associated with abnormal red blood cell turnover, and cost (36). The HbA1c range that indicates high risk of developing diabetes is considered 6.0% to <6.5% by the International Expert Committee (5) and 5.7% to 6.4% by the ADA (1).

**Fructosamine, Glycated Albumin and 1,5-Anhydroglucitol**

Assays of glycated serum proteins, which mostly measure glycated serum albumin, can reflect short-term glycemic control. The fructosamine assay is most commonly used. Since albumin has a short half-life (14-20 days), this test indicates average blood glucose levels over the past few weeks, which can be helpful in certain conditions such as pregnancy or in patients with hemoglobinopathy or abnormal red blood cell turnover. (1, 37). These tests may be affected by hypertriglyceridemia, hyperbilirubinemia, hyperuricemia, hypothyroidism and hyperthyroidism as well as by low serum protein and albumin levels. The relationship between these measures of glycemic control and HbA1c, fasting glucose and mean glucose have been reported in few studies shown below:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Hemoglobin A1c (%)** | **Mean Fasting Glucose (mg/dL)** | **Mean CGM Glucose (mg/dL)** | **Mean (Range) Fructosamine (μmol/L)** | **Mean (Range) Glycated Albumin (%)** | **Mean (Range) 1,5-anhydroglucitol (μg/mL)** |
| 5.4a | 102a |  | 219 (89-240) | 12.2 (5.6-13.5) |  |
|  | 100 b |  | 224.9 | 12.5 | 27.5 |
| 5.7b |  |  | 241.4 | 13.6 | 29.1 |
|  | 126 b |  | 261.7 | 15.0 | 17.9 |
| 6.1a |  |  | 238 | 13.3 (7.9-15.6) |  |
| 6.2a | 126 |  | 236 (159-265) | 13.6 |  |
|  | 126 |  | 250.5-276.4 | 15.5-16.9 | 5.9-15.7 |
| 6.5 b |  |  | 270.2 | 15.6 | 22.7 |
| 6.5c |  |  | 254.7-289.5 | 16.1-18.3 | 5.0-15.3 |
| 7.4d |  | 143 | 293 | 19.6 | 3.4 |
| 7.7 a | 179 |  | 305(266-355) | 18.9(15.7-23.0) |  |
| 7.8d |  | 170 | 312.5 | 22.8 | 4.2 |
| 8.2d |  | 185 | 344 | 24.9 | 6.1 |
| 9.4d |  | 218 | 427 | 30.4 | 11.6 |
| 10.5 a | 269 |  | 445 (356-706) | 30.3 (23.1-51.5) |  |

a-c References 38-40: ARIC study (adults)

d Reference 41: DirecNet study (youth)

CGM: continuous glucose monitoring

Assays of 1,5-anhydroglucitol (1,5-AG) are an alternative measure of hyperglycemia. In the kidney, 1,5-AG is filtered by the glomeruli and reabsorbed in the proximal tubules. This reabsorption is competitively inhibited by glucose. When high glucose levels are associated with glycosuria, there is increased 1,5-AG excretion in the urine and lower serum levels. Concentrations of 1,5-AG reflect hyperglycemia-induced glycosuria over the prior 1-2 weeks. This test may be affected by pregnancy, advanced renal disease,(CKD stages 4-5) and by use of SGLT-2 inhibitors.

There are few of studies demonstrating the usefulness of the fructosamine, glycated albumin and 1,5-AG assays in predicting the development of diabetes-related complications (38, 42). Racial differences have also been reported for these assays (42). Since their clinical usefulness is not well established, testing is generally recommended in situations where HbA1c testing is expected to be inaccurate (e.g. abnormal red blood cell turnover).

**EVALUATION OF HYPOGLYCEMIA**

Symptomatic hypoglycemia is defined clinically using Whipple's triad, which includes the presence of symptoms (confusion, lightheadedness, loss of consciousness, seizure, aberrant behavior, sweating, palpitations, weakness, blurred vision or hunger) at the time of a low plasma glucose level, with improvement of symptoms when plasma glucose levels return to normal (43). The physician should determine if the patient truly has hypoglycemia prior to seeking an etiology. A plasma glucose level < 55 mg/dl (3.1 mmol/l) should raise the suspicion for a hypoglycemic disorder and initiate further evaluation, but many authorities rely on a glucose <40 mg/dl (2.2 mmol/l) as being diagnostic (44). Although symptoms are commonly observed when plasma glucose falls to <55 mg/dl (3.1 mmol/l), levels of <45 mg/dl (2.5 mmol/l) are associated with cognitive dysfunction (neuroglycopenia). Capillary glucose determinations should not be used in the evaluation of hypoglycemic disorders due to their poor accuracy in these situations.

The Endocrine Society has published clinical practice guidelines for the evaluation and management of hypoglycemic disorders (45). In persons without diabetes, drugs or critical illnesses, hormone deficiencies and non-islet cell tumors should be considered based on the clinical findings (46). If the cause of the hypoglycemia is not evident then plasma glucose, insulin, c-peptide, proinsulin, β-hydroxybutyrate, insulin antibodies and screen for oral hypoglycemic drugs should be obtained during an episode of spontaneous hypoglycemia. Glucagon 1 mg IV should then be administered with careful follow up of the glucose response. This will help determine if the condition is related to excessive endogenous insulin production. The diagnosis of pancreatic hyperinsulinemic hypoglycemia is supported by the demonstration that insulin secretion is not suppressed normally when the patient develops hypoglycemia. If testing cannot be conducted during an episode of spontaneous hypoglycemia, the prolonged fast or mixed meal test followed by the administration of glucagon is the most useful diagnostic study.

Some patients who have had bariatric surgery for the treatment of obesity, most commonly Roux-en-Y gastric bypass will develop hypoglycemia. This is associated with abnormal OGTTs and mixed meal tests, abnormal transport of food to the small intestine, and, in some cases, hypersecretion of insulin and incretin hormones (47-50). Spontaneous hypoglycemia has been reported after islet autotransplantation for chronic pancreatitis as well; a deficient glucagon response to hypoglycemia during a mixed meal test has been reported (51).

**Prolonged Fast**

The gold standard test in the evaluation of hypoglycemia is the 72-hour supervised fast. The purpose of the fast is twofold. The first is to diagnose hypoglycemia as the cause of the patient's symptoms. The second is an attempt to determine the etiology of the hypoglycemia. Due to the risk of hypoglycemia, patients should be admitted to the hospital to undergo the fast in a monitored setting. The fast could be initiated in a carefully monitored outpatient facility, with the patient entering the hospital if the fast is not terminated prior to the closing of the site. Baseline bloodwork can include cortisol, growth hormone, glucagon and catecholamines if deficient counterregulation is suspected.

During the fast, patients are allowed no food but can consume non-caloric caffeine-free beverages for up to 72 hours. The onset of the fast is the time of the last food consumption. During the fast all non-essential medications should be discontinued. Simultaneous insulin, c-peptide and glucose samples are obtained at the beginning of the fast and every 4-6 hours thereafter. Once the plasma glucose falls to <60 mg/dl, specimens should be taken every 1-2 hours under close supervision. Patients should continue activity when they are awake. The fast continues until the plasma glucose falls below 45 mg/dl (2.5 mmol/l) [plasma glucose <55 mg/dl (3.1 mmol/L) is recommended in the most recent Endocrine Society guidelines (45)] and symptoms of neuroglucopenia develop, at which time, insulin, glucose, c-peptide, oral insulin secretagogues, proinsulin and beta-hydroxybutyrate levels are obtained and the fast is terminated (44). Additional samples for insulin antibodies, anti-insulin receptor antibodies, IGF-1/IGF-2 and plasma cortisol, glucagon or growth hormone can also be obtained if a non-islet cell tumor, autoimmune etiology, or hormone deficiency is suspected. A glucagon tolerance test is then frequently performed to aid in diagnosis [Glucagon, 1 mg intravenously, administered with careful follow up of the glucose response every 10 minutes for 30 minutes. Further details regarding the glucagon tolerance test are below]. Patients are fed at the conclusion of the test.

The diagnosis of endogenous hyperinsulinism is likely if the patient has neuroglycopenic symptoms, a fall in plasma glucose to <55 mg/dl, inappropriately elevated beta-cell polypeptides (insulin, proinsulin and c-peptide levels; see below table), with undetectable oral insulin secretagogue levels. β-hydroxybutyrate <2.7 mmol/L, and an increase in plasma glucose ≥25 mg/dL (1.4 mmol/L) after intravenous glucagon indicate mediation of the hypoglycemia by either insulin (endogenous or exogenous) or an IGF excess (45).

**Table 14: Distinguishing Causes of Symptomatic Hypoglycemia [glucose < 55 mg/dl (3.0 mmol/l)] After a Prolonged Fast**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Insulin (µU/mL)** | **C-peptide (nmol/L)** | **Proinsulin (pmol/L)** | **Oral hypoglycemic medication** | **Interpretation** |
| »3 | <0.2 | <5 | No | Exogenous insulin |
| ≥3 | ≥0.2 | ≥5 | No | Endogenous insulina |
| ≥3 | ≥0.2 | ≥5 | Yes | Oral hypoglycemic (drug-induced) |
| a Insulinoma, non-insulinoma pancreatogenous hypoglycemia (NIPHS), post gastric bypass hypoglycemia.  |

Adapted from: Cryer, PE, et al. Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94:709-728, 2009

Approximately 75% of patients with insulinomas are diagnosed after a 24 hour fast and 90-94% at 48 hours. Although some experts advocate conducting the prolonged fast for only 48 hours (52), others disagree, arguing that prolonging the fast up to 72 hours minimizes misdiagnosis and maximizes the probability of diagnosing an insulinoma (53).

Limitations of the prolonged fast:

* Normal subjects, especially young women, can occasionally have plasma glucose levels of <40 mg/dl (2.2 mmol/l)
* Rare insulinomas suppress their release of insulin in response to hypoglycemia
* Insulin levels can sometimes be artificially elevated in the presence of anti-insulin antibodies.

**Mixed Meal Test**

For patients with hypoglycemic symptoms several hours after meals, a mixed meal test may be performed. This test has not been well standardized. This test is typically done after an overnight fast. Patients eat a meal similar to one that provokes their symptoms. If this is not possible then a commercial mixed meal may be used. Patients are then observed for several hours. Samples for plasma glucose, insulin, c-peptide, and proinsulin are collected prior to the meal and every 30 minutes thereafter for 5 hours. If symptoms occur prior to the end of the test then additional samples for the above are collected prior to administration of carbohydrates. If Whipple’s triad is demonstrated, testing for oral hypoglycemic drugs and testing for insulin antibodies should be done. Interpretation of test results is the same as for the 72-hour fast or spontaneous hypoglycemia

**Glucagon Tolerance Test**

The glucagon tolerance test serves as a supplemental study to aid in the diagnosis of hypoglycemic disorders when results from the prolonged fast are inconclusive. Following an overnight fast (or at the conclusion of a prolonged fast), 1 mg of glucagon is injected intravenously over 2 minutes. Plasma glucose and insulin levels are measured at baseline, and either 10, 20, and 30 minutes after glucagon, or at 3, 5, 10, 15, 20, and 30 minutes after glucagon injection. In normal patients, maximum insulin response occurs rapidly and usually does not exceed 100 uU/ml (peak insulin 61+19 uU/ml at 3-15 minutes), and the serum glucose levels peak at 20-30 minutes (140 +24 mg/dl) (54).

Insulinoma patients demonstrate an exaggerated insulin response to glucagon, with values often exceeding 160 uU/ml within 15-30 minutes of the injection (peak insulin 93-343 uU/ml at 15 minutes) (46). In the hypoglycemic patient at the conclusion of the prolonged fast, an increase in plasma glucose of >25 mg/dl (1.4 mmol/l) post-glucagon suggests an insulin-mediated etiology (55).

Patients with malnutrition or hepatic disease may be unable to have a hyperglycemic response to glucagon due to depleted hepatic glycogen stores. Insulin responses in these subjects may be increased but not to the degree seen in subjects with an insulinoma. Drugs such as diazoxide, hydrochlorothiazide and diphenylhydantoin can cause false negative results (54). Patients with non-islet cell tumors such as hemangiopericytomas and meningeal sarcomas can have similar glucose elevations (30 mg/dl) as subjects with insulinomas following glucagon injection (56).

Another limitation of the glucagon stimulation test is the failure of some insulinoma patients to hypersecrete insulin following glucagon injection. This problem was reported in 8% of patients with insulinomas in one study (54). In addition, patients with cirrhosis with portocaval anastomosis can have peak insulin levels that are indistinguishable from subjects with insulinomas. Obese subjects and patients with acromegaly can also have exaggerated peak insulin responses, as can patients treated with sulfonylurea drugs and aminophylline.

An additional disadvantage of this test is the danger of causing hypoglycemia after 90-180 min (57) as well as inducing nausea and vomiting. Because of the possibility of severe hypoglycemia, a physician needs to be present during the test.

**Autoimmune Hypoglycemia**

The insulin autoimmune syndrome is a rare condition whereby antibodies, either directed against insulin or against the insulin receptor, are responsible for hypoglycemia. Autoimmune hypoglycemia due to insulin antibodies should be suspected when the hypoglycemia is associated with high insulin levels (usually >100 uU/mL) and incompletely suppressed C-peptide levels. Insulin levels are rarely >100 uU/mL in the presence of hypoglycemia due to an insulinoma. Although these elevated insulin levels can be observed with exogenous insulin administration, the associated c-peptide levels are usually extremely low. Autoimmune hypoglycemia is most often seen in people of Japanese descent but has been described in other populations (58). Autoimmune hypoglycemia may also be due to antibodies to the insulin receptor. These patients will have mildly elevated insulin levels (thought to be due to decreased clearance of insulin) and suppressed c-peptide levels, and may have other autoimmune conditions. Antibodies to insulin and/or proinsulin and insulin receptor antibodies can interfere with the measurements of pancreatic hormones using immunoassays (59, 60). Insulin, proinsulin and/or insulin receptor antibody testing is needed to confirm the diagnosis of autoimmune hypoglycemia. This testing does not need to be done at the time of hypoglycemia.

**C-Peptide Suppression Test**

C-peptide and insulin are secreted in equimolar concentrations in the pancreas, making c-peptide levels a good marker of endogenous insulin secretion. The c-peptide suppression test can be used to test for an insulinoma or to provide supplemental diagnostic information, especially if the results of a supervised fast are not definitive. The c-peptide suppression test must be carefully administered, since the patient is given intravenous insulin to induce hypoglycemia. The advantage of the test is that it is of much shorter duration than the supervised fast.

The c-peptide suppression test is performed following an overnight fast. The procedure is to infuse regular insulin, 0.125 U/kg body weight, intravenously over 60 minutes. Blood samples are obtained from the contralateral arm at 0, 30, 60, 90, and 120 minutes for determination of insulin, c-peptide, and plasma glucose levels. An abnormal result is a lower percentage decrease of c-peptide at 60 minutes compared to normative data appropriately adjusted for the patient's body mass index and age (44). For example, an abnormal result for a 45 year old with a BMI of 25-29 kg/m2 would be <61% suppression of c-peptide at 60 minutes (61). An alternative method (Regular insulin 0.075 IU/kg/hr infused intravenously over 2 hours) using a different classification plot has been proposed (62) but few data using it have been published.

Limitations of this test include the fact that some patients with a documented insulinoma have normal c-peptide levels including normal percent decrease in c-peptide levels. There is also the danger of inducing severe hypoglycemia. In addition, little data concerning the reliability, sensitivity and safety of this test are published.

**REFERENCES**

1. American Diabetes Association. Standards of medical care in patients with diabetes. 2018. Diabetes Care 2018;41(Suppl.1):S1-S159.

2. Siu AL; US Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(11):861-8.

3. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract 2015;21(Suppl.2):1-87.

4. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2018:41(Suppl.1):S13-S27.

5. The International Expert Committee. International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334.

6. [Shaw JE, Zimmet PZ, McCarty D, de Courten M. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000;23 (Suppl 2):B5.](http://www.uptodate.com/contents/epidemiology-presentation-and-diagnosis-of-type-2-diabetes-mellitus-in-children-and-adolescents/abstract/60)

7. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.

8. Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Impact of the new American Diabetes Association and World Health Organization diagnostic criteria for diabetes on subjects from three ethnic groups living in the UK. Nutr Metab Cardiovasc Dis 2000;10:305-309.

9. Sievenpiper JL, Jenkins DJA, Josse RG, Vuksan V. Dilution of the 75-g oral glucose tolerance test improves overall tolerability but not reproducibility in subjects with different body compositions. Diab Res Clin Pract 2001;51:87-95.

10. Sacks DA, Hadden DR, Maresh M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012;35:526–528.

11. Guariguata L, Linnenkamp U Beagley J et al. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103(2):176.

12. [Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007; 30 (Suppl 2):S251-S260.](http://www.uptodate.com/contents/medical-management-and-follow-up-of-gestational-diabetes-mellitus/abstract/39)

13. Moyer VA; US Preventive Services Task Force. Screening for gestational diabetes mellitus; U.S Preventive Services Task Force recommendation. Ann Intern Med. 2014; 160(6):414-20.

14. [International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676.](http://www.uptodate.com/contents/screening-and-diagnosis-of-diabetes-mellitus-during-pregnancy/abstract/3)

15. American College of Obstetricians and Gynecologists Practice Bulletin 180:Gestational Diabetes Mellitus. Obstet Gynecol. 2017;130:e17-37.

16. [HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991-2002.](http://www.uptodate.com/contents/screening-and-diagnosis-of-diabetes-mellitus-during-pregnancy/abstract/22)

17. Vandorsten JP, Dodson WC, Espeland MA et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements 2013;29:1-31.

18. Crowe SM, Mastrobattista JM, Monga M. Oral glucose tolerance test and the preparatory diet. Am J Obstet Gynecol 2000;182:1052-1054.

19 [Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373:1773.](http://www.uptodate.com/contents/medical-management-and-follow-up-of-gestational-diabetes-mellitus/abstract/125)

20. Noctor E, Crowe C, Carmody LA et al. ATLANTIC-DIP Investigators. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol 2016;175:287-97.

21. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, et al. Clinical care guidelines for cystic fibrosis-related diabetes. A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-2708.

22. Moran A, Pillay K, Becker DJ, Acerini CL; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic –fibrosis related diabetes in children and adolescents. Pediatr Diabetes 2014;15(S20):65-76.

23. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J. The Diabetes Prevention Trial-Type 1 Study Group. First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr 2001;138:2244-249.

24. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS et al. Prevalence of detectable c-peptide according to age at diagnosis of type 1 diabetes. Diabetes Care 2015;38:476-481.

25. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.

26. Hanas R, John WG on behalf of the International HgbA1c Consensus Committee. 2013 Update on the Worldwide Standardization of the Hemoglobin A1c Measurement. Pediatric Diabetes 2013.

27. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2005;353:2643-2653.

28. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

29. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Prac 1995;28:103-117.

30. American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm 2018 Consensus Statement. Endocr Pract 2018;24(1):91-120.

31. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.

32. Herman WH, and Cohen RM. Racial and ethnic differences in the relationship between HgbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012;97:1067-1072.

33. Bergenstal RM, Gal RL, Connor CG, Gubitosi-Klug R, Kruger D, Olson BA, Willi SM, Aleppo G, Weinstock RS et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 2017;167:95-102.

34.Wei N, Zhang H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014;37:1048-1051.

35. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994-999.

36. Higgins T. HbA1c for screening and diagnosis of diabetes mellitus. Endocrine 2013;43:266-273.

37. True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol 2009;3:743-747.

38. Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, Coresh J. Prognostic utility of fructosamine and glycated albumin for incident diabetes and microvascular complications. Lancet Daibetes Endocrinol 2014;2:279-288.

39. Selvin E, Warren B, He X, Sacks DB, Saenger AK. Establishment of community-based reference intervals for fructosamine, glycated albumin and 1.5-anhydroglucitol. Clin Chem 2018;64: doi:10.1373/clinchem.2017.285742 in press.

40. Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A1c and fasting glucose. Clin Chem 2012;58:1648-1655.

41. Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, Kollman C. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1.5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 2011;12:690-695.

42. Selvin E, Steffes ME, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011;154:303-309.

43. Whipple AE: The surgical therapy of hyperinsulinism. J Int Chir 1938;3:237-276.

44. Marks V: Recognition and differential diagnosis of spontaneous hypoglycaemia. Clin Endocrinol 1992;37:309.

45. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009;94:709-728.

46. Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, Leroith D, Vigneri R, Koch CA, Roth J. [Tumors, IGF-2 and hypoglycemia: insights from the clinic, the laboratory and the historical archive.](http://www.ncbi.nlm.nih.gov/pubmed/23671155) Endocr Rev 2013;34:798-826.

47. Lee CJ, Brown T, Magnuson TH, Egan JM, Carlson, O, Elahi D. Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia. J Clin Endocrinol Metab 2013;98:E1208-1212.

48. Ritz P, Hanaire H. Post-bypass hypoglycaemia: a review of current findings. Diabetes Metab 2011;37:274-281.

49. Roslin M, Damani T, Oren J, Andrews R, Yatco E, Shah P. Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia. Surg Endosc 2011;25:1926-1932.

50. Desimone ME, Weinstock RS. Non-diabetic hypoglycemia. In www.ENDOTEXT.org. September 23, 2017, published by MDTEXT.COM INC, South Dartmouth MA 02748. PMID: 27099902.

51. Bogachus LD, Bellin MD, Vella A, Robertson RP. Deficient glucagon response to hypoglycemia during a mixed meal in total pancreatectomy/islet autotransplantation recipients. J Clin Endocrinol Metab 2018;103:1522-1529.

52. Hirshberg B, Livi A, Bartlett DL, et al: Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000;85:3222-3226.

53. Service FJ, Natt N: Clinical perspective: the prolonged fast. J Clin EndocrinolMetab 2000;85:3973-3974.

54. Kumar D, Mehtalia SD, Miller LV: Diagnostic use of glucagon-induced insulin response. Studies in patients with insulinoma or other hypoglycemic conditions.Ann Intern Med 1974;80:697-701.

55. Service FJ: Hypoglycemic disorders. N Engl J Med 1995;332:1144-1152.

56. Hoff AO, Vassilopoulou-Sellin R: The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998;82:1585-1592.

57. Marks V, Samols E: Glucagon test for insulinoma: a chemical study in 25 cases. J Clin Path 1968;21:346-352.

58. Luspa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine 2009;88:141-53.

59. Hirata Y, Ishizu H, Ouchi N, Motomura S, Abe M, Hara Y, Wakasugi H, Takahashi I, Sakani H, Tanaka M, Kawano H, Kanesaka T. Insulin autoiummunity in a case with spontaneous hypoglycemia. J Japaneses Diab Soc. 1970;13:312-320.

60. Ismail AAA. The insuiln autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clin Chem Lab Med 2016;54:1715-1724.

61. Service FJ, O'Brien PC, Kao PC, Young Jr WF: C-peptide suppression test: effects of gender, age and body mass index: implications for the diagnosis of insulinoma. J Clin Endocrinol Metab 1992;74:204-210.

62. [Saddig C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Saddig%20C%5BAuthor%5D&cauthor=true&cauthor_uid=11884763), [Bender R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bender%20R%5BAuthor%5D&cauthor=true&cauthor_uid=11884763), [Starke AA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Starke%20AA%5BAuthor%5D&cauthor=true&cauthor_uid=11884763). A new classification plot for the C-peptide suppression test. 2002 ;3(1):16-25.